| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Denali Therapeutics Inc. (DNLI) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 22 sells. DNLI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 26.00M | $625.21M | - | |
| CEO | 296.8K | $7.14M | - | |
| Other | 282.8K | $6.80M | - | |
| Other | 216.6K | $5.21M | - | |
| Dir | 38.2K | $918.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 12, 2020 | Schenkein David P59 | Director | Sell | 30,000 | $70.05 | $2,101,590.00 | -54.5% | |
| Nov 10, 2020 | Schenkein David P59 | Director | Sell | 10,000 | $60.03 | $600,310.00 | -15.4% | |
| Nov 4, 2020 | Schenkein David P59 | Director | Sell | 10,000 | $50.18 | $501,830.00 | -13.3% | |
| Oct 9, 2020 | Ho Carole73 | Chief Medical Officer | Sale+OE | 52,906 | $40.74 | $2,155,602.77 | -9.2% | |
| Sep 10, 2020 | Ho Carole73 | Chief Medical Officer | Sell | 3,689 | $31.00 | $114,359.00 | -2.2% | |
| Aug 12, 2020 | Bratton Douglas K | 10% Owner | Sell | 1,443,247 | $31.65 | $45,678,767.55 | -10.6% | |
| Jun 30, 2020 | Bratton Douglas K | 10% Owner | Sell | 250,000 | $23.97 | $5,993,051.59 | -7.5% | |
| Jun 23, 2020 | Bratton Douglas K | 10% Owner | Sell | 255,000 | $24.72 | $6,304,373.01 | -5.3% | |
| Jun 16, 2020 | Tessier-Lavigne Marc69 | Director | Sell | 400,000 | $26.10 | $10,440,000.00 | -12.7% | |
| Jun 5, 2020 | Bratton Douglas K | 10% Owner | Sell | 1,922,855 | $25.75 | $49,513,516.25 | -12.4% |